ApoE and ApoC-I polymorphisms: Association of genotype with cardiovascular disease phenotype in African Americans

Journal of Lipid Research

Volumn 50, Issue 7, 2009, Pages 1472-1478

  Anuurad, Erdembileg ^a   Yamasaki, Masayuki ^a,b   Shachter, Neil ^c   Pearson, Thomas A ^d   Berglund, Lars ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Apolipoprotein C I; Apolipoprotein E; Coronary artery disease; Ethnicity; Polymorphism

Indexed keywords

APOLIPOPROTEIN C1; APOLIPOPROTEIN E; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HOMOZYGOSITY; HUMAN; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

AFRICAN AMERICANS; APOLIPOPROTEIN C-I; APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 67650510956     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P900012-JLR200     Document Type: Article

References (33)

1. Conde-Knape, K., A. Bensadoun, J. H. Sobel, J. S. Cohn, and N. S. Shachter. 2002. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J. Lipid Res. 43: 2136-2145.
2. Windler, E., Y. Chao, and R. J. Havel. 1980. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins. J. Biol. Chem. 255: 8303-8307.
3. Quarfordt, S. H., G. Michalopoulos, and B. Schirmer. 1982. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J. Biol. Chem. 257: 14642-14647.
4. Jong, M. C., K. W. van Dijk, V. E. Dahlmans, H. Van der Boom, K. Kobayashi, K. Oka, G. Siest, L. Chan, M. H. Hofker, and L. M. Havekes. 1999. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem. J. 338: 281-287.
5. Shachter, N. S., T. Ebara, R. Ramakrishnan, G. Steiner, J. L. Breslow, H. N. Ginsberg, and J. D. Smith. 1996. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J. Clin. Invest. 98: 846-855.
6. Jong, M. C., V. E. Dahlmans, P. J. van Gorp, K. W. van Dijk, M. L. Breuer, M. H. Hofker, and L. M. Havekes. 1996. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J. Clin. Invest. 98: 2259-2267.
7. Jong, M. C., M. J. Gijbels, V. E. Dahlmans, P. J. Gorp, S. J. Koopman, M. Ponec, M. H. Hofker, and L. M. Havekes. 1998. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. J. Clin. Invest. 101: 145-152.
8. Cohn, J. S., M. Tremblay, R. Batal, H. Jacques, L. Veilleux, C. Rodriguez, L. Bernier, O. Mamer, and J. Davignon. 2002. Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hyper-triglyceridemic subjects. J. Lipid Res. 43: 1680-1687.
9. Mahley, R. W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240: 622-630.
10. Moore, R. J., R. M. Chamberlain, and F. R. Khuri. 2004. Apolipoprotein E and the risk of breast cancer in African-American and non-Hispanic white women: a review. Oncology. 66: 79-93.
11. de Knijff, P., and C. M. van Duijn. 1998. Role of APOE in dementia: a critical reappraisal. Haemostasis. 28: 195-201.
12. Utermann, G., M. Hees, and A. Steinmetz. 1977. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature. 269: 604-607.
13. van Bockxmeer, F. M., and C. D. Mamotte. 1992. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet. 340: 879-880.
14. Stengard, J. H., J. Pekkanen, C. Ehnholm, A. Nissinen, and C. F. Sing. 1996. Genotypes with the apolipoprotein epsilon4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men. Hum. Genet. 97: 677-684.
15. Gerdes, L. U., C. Gerdes, K. Kervinen, M. Savolainen, I. C. Klausen, P. S. Hansen, Y. A. Kesaniemi, and O. Faergeman. 2000. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation. 101: 1366-1371.
16. Anuurad, E., J. Rubin, G. Lu, T. A. Pearson, S. Holleran, R. Ramakrishnan, and L. Berglund. 2006. Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol. J. Lipid Res. 47: 2475-2481.
17. Smit, M., E. van der Kooij-Meijs, L. P. Woudt, L. M. Havekes, and R. R. Frants. 1988. Exact localization of the familial dysbetalipoproteinemia associated HpaI restriction site in the promoter region of the APOC1 gene. Biochem. Biophys. Res. Commun. 152: 1282-1288.
18. Xu, Y., L. Berglund, R. Ramakrishnan, R. Mayeux, C. Ngai, S. Holleran, B. Tycko, T. Leff, and N. S. Shachter. 1999. A common Hpa I RFLP of apolipoprotein C-I increases gene transcription and exhibits an ethnically distinct pattern of linkage disequilibrium with the alleles of apolipoprotein E. J. Lipid Res. 40: 50-58.
19. Seixas, S., M. J. Trovoada, and J. Rocha. 1999. Haplotype analysis of the apolipoprotein E and apolipoprotein C1 loci in Portugal and Sao Tome e Principe (Gulf of Guinea): linkage disequilibrium evidence that APOE*4 is the ancestral APOE allele. Hum. Biol. 71: 1001-1008.
20. Cohn, J. S., M. Tremblay, L. Boulet, H. Jacques, J. Davignon, M. Roy, and L. Bernier. 2003. Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism. Atherosclerosis. 169: 63-70.
21. Anuurad, E., G. Lu, J. Rubin, T. A. Pearson, and L. Berglund. 2007. ApoE genotype affects allele-specific apo[a] levels for large apo[a] sizes in African Americans: the Harlem-Basset Study. J. Lipid Res. 48: 693-698.
22. McGowan, M. W., J. D. Artiss, D. R. Strandbergh, and B. Zak. 1983. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin. Chem. 29: 538-542.
23. Allain, C. C., L. S. Poon, C. S. Chan, W. Richmond, and P. C. Fu. 1974. Enzymatic determination of total serum cholesterol. Clin. Chem. 20: 470-475.
24. Warnick, G. R., J. Benderson, and J. J. Albers. 1982. Dextran sulfate-Mg21+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin. Chem. 28: 1379-1388.
25. Friedewald, W. T., R. I. Levy, and D. S. Fredrickson. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18: 499-502.
26. Levy, J. C., D. R. Matthews, and M. P. Hermans. 1998. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 21: 2191-2192.
27. Adler, A. I., J. C. Levy, D. R. Matthews, I. M. Stratton, G. Hines, and R. R. Holman. 2005. Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diabet. Med. 22: 306-311.
28. Hixson, J. E., and D. T. Vernier. 1990. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31: 545-548.
29. Windler, E. E., P. T. Kovanen, Y. S. Chao, M. S. Brown, R. J. Havel, and J. L. Goldstein. 1980. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J. Biol. Chem. 255: 10464-10471.
30. Sehayek, E., and S. Eisenberg. 1991. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 266: 18259-18267.
31. Gautier, T., D. Masson, J. P. de Barros, A. Athias, P. Gambert, D. Aunis, M. H. Metz-Boutigue, and L. Lagrost. 2000. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J. Biol. Chem. 275: 37504-37509.
32. Soutar, A. K., C. W. Garner, H. N. Baker, J. T. Sparrow, R. L. Jackson, A. M. Gotto, and L. C. Smith. 1975. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry. 14: 3057-3064.
33. Asztalos, B. F., E. J. Schaefer, K. V. Horvath, S. Yamashita, M. Miller, G. Franceschini, and L. Calabresi. 2007. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J. Lipid Res. 48: 592-599.